Key facts
- This page summarizes Patrick J. Balthrop's Form 4 filing for MAXCYTE, INC. (MXCT).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 13 Jun 2024, 17:30.
Patrick J. Balthrop - 11 Jun 2024 Form 4 Insider Report for MAXCYTE, INC. (MXCT)
- Reporting relationship
- Director
- Issuer ticker
- MXCT
- Reported as of
- 11 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 13 Jun 2024, 17:30:16 UTC
- Prior SEC filing
- 23 Jun 2023
- Next SEC filing
- 23 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brian Leaf, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Patrick J. Balthrop filed Form 4 for MAXCYTE, INC. (MXCT) on 13 Jun 2024.
Change
- Previous filing in this sequence was filed on 23 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MXCT
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +21,367
- Change %
- Price
- $0.000000
- Shares after
- 21,367
- Date
- 11 Jun 2024
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MXCT
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +40,701
- Change %
- Price
- $0.000000
- Shares after
- 40,701
- Date
- 11 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 40,701
- Exercise price
- $4.68
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
Footnote F2
This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 11, 2025, subject to the reporting person's continuous service as of such vesting date.